A citation-based method for searching scientific literature

Annette Haacke, Sarah A Broadley, Raina Boteva, Nikolay Tzvetkov, F Ulrich Hartl, Peter Breuer. Hum Mol Genet 2006
Times Cited: 93

A Dürr, G Stevanin, G Cancel, C Duyckaerts, N Abbas, O Didierjean, H Chneiweiss, A Benomar, O Lyon-Caen, J Julien, M Serdaru, C Penet, Y Agid, A Brice. Ann Neurol 1996
Times Cited: 337

List of shared articles

Times cited

Unravelling Endogenous MicroRNA System Dysfunction as a New Pathophysiological Mechanism in Machado-Joseph Disease.
Vitor Carmona, Janete Cunha-Santos, Isabel Onofre, Ana Teresa Simões, Udaya Vijayakumar, Beverly L Davidson, Luís Pereira de Almeida. Mol Ther 2017

Valosin-containing protein (VCP/p97) is an activator of wild-type ataxin-3.
Mário N Laço, Luisa Cortes, Sue M Travis, Henry L Paulson, A Cristina Rego. PLoS One 2012

PolyQ-expanded ataxin-3 interacts with full-length ataxin-3 in a polyQ length-dependent manner.
Na-Li Jia, Er-Kang Fei, Zheng Ying, Hong-Feng Wang, Guang-Hui Wang. Neurosci Bull 2008

Calpain inhibition reduces ataxin-3 cleavage alleviating neuropathology and motor impairments in mouse models of Machado-Joseph disease.
Ana Teresa Simões, Nélio Gonçalves, Rui Jorge Nobre, Carlos Bandeira Duarte, Luís Pereira de Almeida. Hum Mol Genet 2014

A Novel Calpain Inhibitor Compound Has Protective Effects on a Zebrafish Model of Spinocerebellar Ataxia Type 3.
Katherine J Robinson, Kristy Yuan, Stuart K Plenderleith, Maxinne Watchon, Angela S Laird. Cells 2021

Toward understanding Machado-Joseph disease.
Maria do Carmo Costa, Henry L Paulson. Prog Neurobiol 2012

Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease.
Carlos A Matos, Sandra de Macedo-Ribeiro, Ana Luísa Carvalho. Prog Neurobiol 2011

Ataxin-3 protein and RNA toxicity in spinocerebellar ataxia type 3: current insights and emerging therapeutic strategies.
Melvin M Evers, Lodewijk J A Toonen, Willeke M C van Roon-Mom. Mol Neurobiol 2014

n-Butylidenephthalide exhibits protection against neurotoxicity through regulation of tryptophan 2, 3 dioxygenase in spinocerebellar ataxia type 3.
Karthyayani Rajamani, Jen-Wei Liu, Cheng-Han Wu, I-Tsang Chiang, Deng-Huwei You, Si-Yin Lin, Dean-Kuo Hsieh, Shinn-Zong Lin, Horng-Jyh Harn, Tzyy-Wen Chiou. Neuropharmacology 2017

Identification of the calpain-generated toxic fragment of ataxin-3 protein provides new avenues for therapy of Machado-Joseph disease| Spinocerebellar ataxia type 3.
Ana Teresa Simões, Vítor Carmona, Joana Duarte-Neves, Janete Cunha-Santos, Luís Pereira de Almeida. Neuropathol Appl Neurobiol 2021

Flow cytometry allows rapid detection of protein aggregates in cellular and zebrafish models of spinocerebellar ataxia 3.
Katherine J Robinson, Madelaine C Tym, Alison Hogan, Maxinne Watchon, Kristy C Yuan, Stuart K Plenderleith, Emily K Don, Angela S Laird. Dis Model Mech 2021

Machado-Joseph disease/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapy.
Carlos A Matos, Luís Pereira de Almeida, Clévio Nóbrega. J Neurochem 2019

From Pathogenesis to Novel Therapeutics for Spinocerebellar Ataxia Type 3: Evading Potholes on the Way to Translation.
Jorge Diogo Da Silva, Andreia Teixeira-Castro, Patrícia Maciel. Neurotherapeutics 2019

SCA3: neurological features, pathogenesis and animal models.
Olaf Riess, Udo Rüb, Annalisa Pastore, Peter Bauer, Ludger Schöls. Cerebellum 2008

A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice.
Veronica F Colomer Gould, Daniel Goti, Donna Pearce, Guillermo A Gonzalez, Hong Gao, Mario Bermudez de Leon, Nancy A Jenkins, Neal G Copeland, Christopher A Ross, Dale R Brown. Neurobiol Dis 2007

Physiological and pathophysiological characteristics of ataxin-3 isoforms.
Daniel Weishäupl, Juliane Schneider, Barbara Peixoto Pinheiro, Corinna Ruess, Sandra Maria Dold, Felix von Zweydorf, Christian Johannes Gloeckner, Jana Schmidt, Olaf Riess, Thorsten Schmidt. J Biol Chem 2019